Abstract

Antimicrobial peptide (Piscidin-1) is an effective natural polypeptide, which has great influence and potential on porcine epidemic diarrhea virus (PEDV) and pseudorabies virus (PRV). As an alternative antibiotic substitute, Piscidin-1 was subjected for pharmacokinetics study with three administration routes (i.v, i.m, and p.o) after a single dose of 2 mg/kg in rats and preliminary pharmacodynamics including antiviral activity in cell against PEDV and PRV. Based on 50 percent tissue culture infective dose (TCID50), there were about 2 and 10% virus survived ratios for Piscidin-1 against PRV and PEDV, respectively. The plaque test showed 1 and 2 μg/ml Piscidin-1 could eliminate 95% PRV and 85% PEDV, respectively. The main pharmacokinetics parameters of Cmax, AUC0−∞, Ke, t1/2, Tmax, MRT, and Clb in plasma were not applicable value, 25.9 μg*h/ml, 0.041 h−1, 16.97 h, not available value, 22.77 h, 0.067 L/h*kg after i.v administration, 2.37 μg/ml, 18.95 μg*h/ml, 0.029 h−1, 23.50 h, 0.33 h, 30.12 h, 0.095 L/h*kg after i.m administration and 0.73 μg/ml, 9.63 μg*h/ml, 0.036 h−1, 19.46 h, 0.50 h, 26.76 h, 0.171 L/h*kg after p.o administration. The bioavailability values after i.m and p.o administrations were calculated as 73.17 and 37.18%, respectively. The i.m administration was selected for pharmacokinetics study in ileum content against PEDV. The main pharmacokinetic parameters of Cmax, AUC0−∞, Ke, t1/2, Tmax, MRT, and Clb in ileum content were 1.67 μg/ml, 78.40 μg*h/ml, 0.034 h−1, 20.16 h, 8.12 h, 36.45 h, 0.026 L/h*kg. The Cmax values in plasma (2.37 μg/ml) and ileum content (1.67 μg/ml) were higher than the effective inhibitory concentration determined in the plaque test, and this indicates that Piscidin-1 might have effective inhibition effect against PRV and PEDV after administration of 2 mg/kg i.m. The results of this study represent the first investigations toward the pharmacokinetic characteristics of piscidin-1 in plasma upon three different administration routes, among which i.m. resulted in the highest bioavailability (73.17%). Furthermore, the pharmacokinetics study of ileum content indicated Piscidin-1 might have good effect against PEDV and could be regarded as an alternative antibiotic in clinical veterinary in the future study.

Highlights

  • With the rapid development of bacterial resistance, the new antibiotics exploration is entering researchers’ vision

  • The plaque reduction assay for pseudorabies virus (PRV) and Porcine epidemic diarrhea virus (PEDV) were performed after exposure to a serial of Piscidin-1 concentrations (0, 0.5, 1, 2, 5, 10, 25 μg/ml)

  • 1 and 2 μg/ml Piscidin-1 could significantly eliminate 95 and 85% plaque forming for PRV and PEDV, respectively (Figure 2)

Read more

Summary

Introduction

With the rapid development of bacterial resistance, the new antibiotics exploration is entering researchers’ vision. Piscidin 1 has been reported to have the best antimicrobial activity of all piscidin family members against pathogenic bacteria such as Escherichia coli, Pseudomonas aeruginosa, B. subtilis, S. epidermidis, and Staphylococcus aureus with a low minimum inhibitory concentration (MIC) (≤ 5.14 μg/ml), and most of the previously published reports focus on the activity and mechanism against pathogens (Lee et al, 2014). It would focus on the pharmacologic action against viruses (PEDV and PRV) and in vivo pharmacokinetics (PK) profiles in pigs in this study

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call